Expression levels of Gb3/CD77 synthase together with Gb3/CD77 antigen were analyzed using human hematopoietic tumor cell lines and normal cells. Among about 40 kinds of cells, Burkitt lymphoma cells showed the highest gene expression concomitant with the expression levels of Gb3/CD77. Unexpectedly, megakaryoblastic leukemia lines also expressed fairly high levels of mRNA of Gb3/CD77 synthase and its product. A megakaryoblastic leukemia line, MEG-01 was sensitive to verotoxins from Escherichia coli O157 and apoptosis was induced via the caspase pathway. We also demonstrated that the cell surface Gb3/CD77 expression was reduced on differentiated MEG-01 although the mRNA level of the ␣1,4Gal-T gene increased. In this case, the localization of Gb3/CD77 was changed from the cell surface to the cytoplasm as stained with a granular pattern, co-localizing with platelet GPIIb-IIIa, indicating that some of them were platelet precursors. Small particles outside of cells also showed similar staining patterns. These results agreed with the previous report that platelets produced in mature megakaryoblasts abundantly contained Gb3/CD77 antigen. Here, we propose the possibility that verotoxins bind immature megakaryoblasts and induce their apoptosis, leading to the arrest of platelet generation in the bone marrow. This may be one of the causes of thrombocytopenia in patients with hemolytic uremic syndrome.
normal hematopoietic cells, a subset of tonsillar B lymphocytes in the germinal center expressed Gb3/CD77 (7), suggesting that Gb3/CD77 is a differentiation antigen expressed at a very restricted stage of B cell development (8) . Erythrocytes also abundantly synthesize Gb3/CD77 as well as globoside, GalNAc␤1,3-Gb3, although they are difficult to detect using antibodies.
Gb3/CD77 is closely associated with apoptosis of immature B cells, since germinal center B lymphocytes expressing Gb3/ CD77 undergo rapid and spontaneous apoptosis when isolated and cultured in vitro (8) . Burkitt lymphoma cells expressing Gb3/CD77 were also induced to enter apoptosis upon culture at low serum concentration or cross-linking by anti-immunoglobulin M antibodies (9) . These findings suggested that Gb3/CD77 is expressed on death-committed cells, or it is involved in the B cell selection.
Gb3/CD77 is also well known to be a receptor for verotoxins (VTs) from Escherichia coli O157 strain, and to mediate apoptosis of vascular endothelial cells in the kidney and intestinal epithelial cells, resulting in the occurrence of hemolytic uremic syndrome (HUS) (10) . Molecular mechanisms for VT-induced apoptosis have been clarified, i.e. binding of the toxin B subunit (7.7 kDa) and subsequent invasion of the A subunit (32 kDa), resulting in the destruction of ribosomal RNA and the inhibition of protein synthesis (11) . There have been a few studies that reported a single B subunit alone can transmit the signals including that for apoptosis (12) .
Gb3/CD77 is synthesized by the action of Gb3/CD77 synthase (␣1,4-galactosyltransferase, ␣1,4Gal-T), the cDNA of which was isolated recently using a eukaryocyte expression cloning system (13) . This gene is mainly expressed in the heart, kidney, spleen, and liver in addition to placenta and testis in normal human tissues (13) , suggesting the roles of its products in the circulation and immune systems. However, genetic mechanisms for the expression of Gb3/CD77 and its implication in the hematopoietic cells have not yet been analyzed.
In the present study, we analyzed the expression levels of the Gb3/CD77 synthase gene and the direct product, Gb3/CD77, in human hematopoietic tumor lines and normal cells. As expected, Burkitt lymphoma cells showed the highest expression levels of both the synthase gene and its product. Surprisingly, we found that megakaryoblastic leukemia cells also express high levels of Gb3/CD77 based on the up-regulation of the ␣1,4Gal-T gene, and that MEG-01, one of megakaryoblastic leukemia lines underwent apoptosis with VTs via the caspase pathway. Expression of Gb3/CD77 in platelets has been reported (14) , but there have been many arguments on the binding of verotoxins to platelets (15) , and on the effects of the toxins on platelets (16, 17) . In particular, the sensitivity of platelets to VTs appears to be a critical point to understand the pathogenesis of HUS (18) . Here, we demonstrated the regulation of Gb3/CD77 antigen and the Gb3/CD77 synthase gene, and the distribution of the Gb3/CD77 antigen during induced differentiation of human megakaryoblastic leukemia cells. The implication of Gb3/CD77 expression in the megakaryoblast/ platelet lineage for the pathogenesis of HUS was discussed.
EXPERIMENTAL PROCEDURES
Cell Culture-Cell lines used in this study were maintained in RPMI 1640 containing 10% fetal calf serum. Burkitt lymphoma cell lines, Ramos and HS-Sultan, myeloma cell lines, GM-1311 and IM-9 were obtained from the Japan Health Science Foundation. EBV-B cell lines were established in our laboratory. BALL-1 and NALM-1 were from Dr. Ueda at Nagoya City University. Sommer and MT-4 were from Dr. Shiku at Mie University. Megakaryoblastic leukemia cell lines, CMS, CMK, and CMY, were established at Chiba University. All other cell lines were as described previously (19, 20) .
Human Hematopoietic Cells-Mononuclear cells were isolated from heparinized peripheral blood samples of healthy donors using FicollHypaque (Amersham Biosciences Inc.). Lymphocytes were stimulated in the presence of concanavalin A (10 g/ml) in RPMI 1640 with 10% fetal calf serum for 3 days. Erythrocytes were obtained from the sedimented layer of the Ficoll preparation, and used for flow cytometry after washing with PBS. Platelets were obtained from the platelet-rich plasma using 0.5% EDTA/PBS, and used for flow cytometric analysis using the same buffer at the washing steps.
Flow Cytometry-Expression of Gb3/CD77 and GPIIb-IIIa was analyzed by flow cytometry (Becton Dickinson) using mAb38.13(rat IgM) (4) and HPL-2 (mouse IgG) (21) as described previously (13) .
Northern Blot Analysis-Total RNA was prepared using TRIZOL Reagent TM (Invitrogen) according to the manufacturer's instructions. Fifteen g each of total RNA was electrophoresed and blotted onto a nylon membrane (GeneScreen Plus) (PerkinElmer Life Sciences). They were hybridized with [ 32 P]dCTP-labeled ␣1,4Gal-T cDNA probe as previously described (13) .
Western Immunoblotting-Cells were lysed with a lysis buffer (20 mM Tris-HCl, pH 7.4, containing 0.15 M NaCl, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride (Sigma), and 5 g/ml aprotinin). Cell lysate (derived from 2.5 ϫ 10 5 cells) was applied for SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Millipore). Af- ; open square, 25; closed triangle, 100 ng/ml VT-2. B, cytoplasmic DNA prepared from MEG-01 after cultivation with VT-2 (20 ng/ml) for 24 h as described under "Experimental Procedures." M, size marker. C, Westen blotting of caspase-3. MEG-01 was cultured in the presence of VT-2 (20 ng/ml) for various durations and the cell lysate was prepared for Western blotting. Immunoblotting was performed as described under "Experimental Procedures." The 32-and 17-kDa bands were procaspase-3 and an activated caspase-3, respectively.
ter blocking with 5% skim milk/PBS for 12 h at 4°C, the membrane was incubated with the first antibody at room temperature for 1 h and then washed with T-PBS (PBS containing 0.05% Tween 20) three times, and incubated with horseradish peroxidase-linked anti-rabbit IgG (HϩL) (New England BioLabs) for caspase 3 and horseradish peroxidaselinked anti-mouse IgG (HϩL) (Zymed Laboratories Inc.) for GP-IIIa for 1 h. Detection was performed using an ECL system (Amersham Biosciences Inc.) according to the manufacturer's instructions.
MTT Assay-MTT assay was performed using cells prepared in 96-well plates (5 ϫ 10 3 cells/well) and cultured in the presence or absence of VT-2. The assay was performed by triplicate samples. To quantify the cell proliferation, 20 l of 5 mg/ml MTT (Sigma) in phosphate-buffered saline was added to each well. After incubation for 6 h at 37°C, 150 l of n-propyl alcohol containing 0.1% Nonidet P-40 and 4 mM HCl was added. The color reaction was quantitated using an automatic plate reader IMMUNO-MINI NJ-2300 (Nihon InterMed, Tokyo, Japan) at 590 nm with a reference filter of 620 nm.
Treatment with Caspase Inhibitor-MEG-01 was treated with 30 M z-VAD-FMK (Peptide Institute Inc., Osaka, Japan) for 1 h, then cultured in the presence of VT-2 as described previously (13) .
Ladder Formation-Cells were cultured in the presence or absence of VT-2 (20 ng/ml). After 24 h, 2 ϫ 10 6 cells were collected and the pellets were lysed in 300 l of lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM EDTA, and 0.5% Triton X-100) for 10 min at 4°C. After centrifugation, the supernatants were collected, and 2 l of RNase (10 mg/ml) and 2 l of Protenase K (10 mg/ml) were added. After incubation for 1 h at 37°C, the fragmented DNA was 2-propanol precipitated. Electrophoresis was conducted using precipitated DNA in a 2% agarose gel containing ethidium bromide (0.5 g/ml), and the DNA ladder was visualized under UV.
Glycolipid Extraction and TLC-Glycolipid extraction and TLC were performed as described previously (22) . Briefly, glycolipids were extracted from 3 ϫ 10 7 cells using chloroform/methanol (2:1, 1:1, and 1:2) sequentially. TLC plates (Merck, Darmstadt) using the solvent system of chloroform, methanol, 0.22% CaCl 2 (60:35:8) and sprayed by orcinol. For a standard, a neutral glycolipid fraction from human erythrocytes was used (22) .
Sialidase Treatment-Sialidase (1.25 units/ml; from Vibrio cholerae, Sigma) was added to 1 ϫ 10 6 cells/0.1-ml suspension and incubated for 1 h at 37°C. After treatment, cells were washed with PBS and analyzed for the expression of Gb3/CD77 with flow cytometry.
Cytostaining-To analyze the intracellular localization of Gb3/CD77 and GPIIb-IIIa, cells grown on a cover glass were fixed in cold acetone/ PBS (9:1) at Ϫ20°C for 10 min. After blocking with 5% bovine serum albumin/PBS for 1 h, they were immunostained with anti-Gb3 mAb (38.13) or anti-GPIIb-IIIa mAb (HPL-2) and FITC-conjugated rabbit anti-rat IgM or Cy3-conjugated goat anti-rat IgM (Jackson Immunoresearch LAB., Inc) for anti-Gb3 mAb and FITC-conjugated goat antimouse IgG for anti-GPIIb-IIIa mAb. The staining was observed using Radiance TM confocal imaging system (Bio-Rad).
Induction of Differentiation-MEG-01 cells (1 ϫ 10
6 cells/ml) were treated with phorbol 12-myristate 13-acetate (TPA) (1 ϫ 10 Ϫ8 M) for 1-3 days as described previously (23) .
Hemoglobin Determination-One percent suspension of human red blood cells in PBS was incubated with 0, 1.5, 6.25, 25, and 100 ng/ml VT-2 at 37°C for 24 h, then cells were pelleted and the supernatants were collected. The visible light absorbance spectrum of the supernatants at 414 nm were determined. The supernatants of human red blood cells lysed with distilled water were used as a positive control. Ϫ8 M TPA and the expressions of Gb3/CD77 and GPIIb-IIIa were analyzed on days 0, 1, 2, and 3 as described in the legend for Fig. 3 .
RESULTS

␣1,4Gal-T Gene Is Highly Expressed in Burkitt Lymphoma
Gb3/CD77 Expression in Megakaryoblasts/Platelets
erythrocytes, and platelets were examined for the surface expression of Gb3/CD77. All Burkitt lymphoma cells expressed high levels of Gb3/CD77 irrespective of EBV positivity. Accordingly, many showed very high levels of the mRNA (Fig. 1, A and  B) . Although one myeloma cell line exhibited high levels of mRNA, Gb3/CD77 expression was not necessarily high. Of 7 EBV-B lines, 6 showed low levels of ␣1,4Gal-T mRNA, while the expression levels of the product were null or very low. Then, 1 B-ALL, 6 T-ALL, 6 HTLV-I ϩ or ATL, 2 null ALL, 1 AproL, 1 NK-like leukemia, and 1 erythroleukemia lines were examined, none of them expressed either Gb3/CD77 or ␣1,4Gal-T mRNA. Surprisingly, two of 4 megakaryoblastic leukemia cell lines exhibited fairly high levels of Gb3/CD77, and the corresponding expression of the ␣1,4 Gal-T gene was observed in both, indicating that some populations of megakaryoblasts express Gb3/ CD77. Mononuclear cells and erythrocytes were completely negative (Fig. 2) . Platelets expressed very low levels of Gb3/ CD77 on the cell surface. Thus, the expression levels of Gb3/ CD77 mostly correlated with those of mRNA of ␣1,4Gal-T. Northern blots of the lactosylceramide synthase gene revealed no relationship with Gb3/CD77 expression (data not shown).
Reciprocal Expression of Gb3/CD77 and GPIIb-IIIa in Megakaryoblastic Leukemia Lines-In the current culture conditions, those lines showed 3 pattens in terms of expression levels of Gb3/CD77 and GPIIb-IIIa, i.e. high Gb3/CD77 and low GPIIb-IIIa (MEG-01, CMS), low Gb3/CD77 and moderate GPIIb-IIIa (CMK), and no Gb3/CD77 and high GPIIb-IIIa (CMY) (Fig. 3, a-d) . GPIIb-IIIa is the major platelet integrin receptor characterized by RGDS-dependent binding to fibronectin, von Willebrand factor, fibrinogen, and vitronectin (24) . These findings suggested that maturation of megakaryoblasts resulted in the reduced surface expression of Gb3/CD77. In addition, Gb3/CD77 was poorly detected in platelets, i.e. 0 -7% positive in five individuals examined with flow cytometry, while GPIIb-IIIa expression was very high (Fig. 3, e and f) .
Megakaryoblasts Undergo Apoptosis with VTs via Caspase 3 Activation-MEG-01 cells were exposed to VT-2 to examine the sensitivity to VT-2. Cell growth was suppressed by VT-2 in a dose-dependent manner (Fig. 4A) , and a DNA ladder was formed only in the VT-2-treated samples (Fig. 4B) . Furthermore, activation of caspase 3 was also observed from 6 h after treatment (Fig. 4C) . To confirm that apoptosis was induced using the caspase cascade in MEG-01, caspase inhibitor z-VAD was added to the culture medium for 1 h before treatment with VT-2. At 12 h after adding VT-2, dying MEG-01 cells were observed (Fig. 5A, middle) , although MEG-01 cells pretreated with z-VAD were apparently viable and indistinguishable from the VT-untreated one (Fig. 5A, right) , indicating that apoptosis of MEG-01 with VT-2 was mediated via the caspase cascade. The activated caspase 3 (17 kDa) was detected in the lysate of MEG-01 cultured with VT-2, although the activated form was not detected in the sample treated with z-VAD (Fig. 5B) . In addition, platelets were treated with VTs in PBS or fetal calf serum-containing medium for 24 h, showing no morphological changes at any conditions at all (Fig. 5A) .
Reduced Gb3/CD77 Expression during the Induced Differentiation of MEG-01-Then, Gb3/CD77 expression during the induced differentiation of MEG-01 cells was analyzed. The differentiation after TPA treatment was confirmed by the increased expression of GPIIb-IIIa as well as characteristic morphological changes (data not shown) as previously reported (23) . Along with the differentiation, surface expression of Gb3/ CD77 was reduced (Fig. 6 ). This result was in good accordance with the reciprocal expression pattern of Gb3/CD77 and GPIIbIIIa detected among several megakaryoblastic leukemia cell lines (Fig. 3) . ␣1,4Gal-T Gene Was Up-regulated during the Induced Differentiation-To investigate the transcriptional regulation of the ␣1,4Gal-T gene during the induced differentiation, Northern blotting was performed. As shown in Fig. 7 , the mRNA levels were relatively increased at 1 day after TPA treatment and sustained high levels, suggesting that the total amount of Gb3/CD77 might not be decreased, although Gb3/CD77 expression at the cell surface was reduced. To analyze total amount of Gb3/CD77 in MEG-01 before and after TPA treatment, neutral glycolipid fractions were compared on TLC. Gb3/CD77 was a major component in the neutral glycolipids in MEG-01, and the intensity of Gb3/CD77 bands after TPA treatment was increased compared with that of untreated cells (Fig. 7C) . Western immunoblotting of GPIIb-IIIa revealed the induced expression of GPIIIa after TPA treatment coincidently with cell surface expression of GPIIb-IIIa (Fig. 7D) .
Expression of Gb3/CD77 after Sialidase Treatment on MEG-01-Cell surface expression of Gb3/CD77 on TPA-treated MEG-01 was decreased, and whether the increased Gb3 crypticity induced its reduced cell surface expression was analyzed by sialidase treatment of MEG-01 at 2 days after TPA treatment. Surface expression of Gb3/CD77 was slightly increased after sialidase treatment, but not so much as TPA untreated MEG-01, indicating that increased crypticity did not contribute so much in the reduction of the surface expression of Gb3/CD77 (Fig. 8A) . The effects of the sialidase treatment on the GPIIb-IIIa expression was also analyzed, showing no change (Fig. 8B) . The sialidase from Clostridium perfringens showed essentially the same results. The efficiency of the sialidase treatment was confirmed by loss of GD3 expression on SK-MEL-28 melanoma cells after sialidase treatment with the same condition (data not shown).
Changes of Intracellular Localization of Gb3/CD77 during the Differentiation-While Gb3/CD77 was stained mainly in a homogenous pattern on the cell surface and partly in the cytoplasm of the untreated MEG-01 (Fig. 9) , it was stained more strongly and with a granular pattern in the TPA-treated cells. Stained granules were present throughout the cytoplasm, and small particles present outside of cells were also stained by the anti-Gb3/CD77 antibody. These results suggested that surface Gb3/CD77 moved to the cytoplasm probably to the platelet precursor, and some of them were released from the differentiated megakaryocytes. As for GPIIb-IIIa, it was stained definitely only after TPA treatment indicating the induction of the differentiation. Extracellular particles were also positive for GPIIb-IIIa, suggesting that they were platelet precursor generated in the cytoplasm of MEG-O1 and released as a result of the megakaryocyte maturation (Fig. 9A) . In the cytostaining, platelets expressed Gb3/CD77 weakly and GPIIb-IIIa strongly (Fig. 9B) . However, particles expressing both Gb3/CD77 and GPIIb-IIIa were a relatively minor population. The Gb3/CD77 single positive was major, and GPIIb-IIIa single positive was also present, although not as a dominant population. When Gb3/CD77 and GPIIb-IIIa staining were merged, the majority of the cytoplasmic region was double stained (Fig. 9C) , indicating the possibility that cytoplasmic particles expressing both antigens might be platelet precursors. The treatment of the fixed cells with Triton X-100 for permeabilization resulted in slightly weaker but essentially same staining compared with those with acetone treatment (data not shown).
Immature Megakaryoblasts Are Sensitive to VTs-MEG-01 cells, both untreated cells and TPA-treated cells, were exposed to VT-2 to compare the sensitivity to the toxins. Untreated MEG-01 clearly exhibited a DNA ladder more intensely than the TPA-treated one (Fig. 10) , indicating that expression levels of Gb3/CD77 were actually regulating the sensitivity to cytotoxicity with VT-2.
DISCUSSION
Among 40 kinds of human hematopoietic tumor cell lines or normal cells, Burkitt lymphoma cells clearly showed high expression levels of the Gb3/CD77 synthase gene in accordance with the high expression of Gb3/CD77 antigen. Surprisingly, megakaryoblastic leukemia cell lines also expressed high levels of both the Gb3/CD77 synthase gene and its products. These findings suggested that Gb3/CD77 expression was mainly regulated at the transcriptional level of the Gb3/CD77 synthase gene. However, it is necessary to consider that expression levels of Gb3/CD77 may also be affected by the availability of the precursor lactosylceramide, and by the conversion rate of Gb3/ CD77 to more complex structures such as globoside. In particular, EB-B cells exhibited fairly high expression levels of Gb3/ CD77 synthase gene, while Gb3/CD77 expression is minimal or null. This may be due to the crypticity of the antigen (25) or the lack of lactosylceramide, and remains to be clarified. This is the first study to detect Gb3/CD77 expression on megakaryoblasts, although the finding that human platelets contain a high level of Gb3/CD77 as a major glycolipid is well known (26 -28) . Furthermore, we demonstrated here that they are also sensitive to VTs and undergo apoptosis via the activation of caspases as shown in other cells (29) . As the molecular mechanisms for the VT-mediated apoptosis, two major pathways are involved. First, the cytotoxic effects of VTs were originally suggested to be caused by an A-subunit of the toxin containing RNA N-glycohydrolase activity. The inhibition of protein synthesis with the A-subunit leads to apoptosis (30 -32) . Recently, B subunit, a binding subunit of the toxin (33) , has also been shown to induce apoptosis (34) . The finding that cross-linking of Gb3/CD77 triggered intracellu- In the present study, it was demonstrated that immature megakaryoblasts are also sensitive to VTs and are induced to apoptosis based on the Gb3/CD77 expression. The activation of caspase 3 with VTs, and inhibition of MEG-01 destruction and caspase 3 activation with z-VAD indicated that megakaryoblasts undergo apoptosis via caspase activation cascade. The sensitivity to apoptosis correlated with Gb3/CD77 expression levels. All these findings suggested that less differentiated megakaryoblasts are more sensitive to VT-induced apoptosis, and the final product, platelets are insensitive to VTs (Fig. 10) .
HUS is a clinical syndrome characterized by acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia which often follows infection by Shiga toxin-or VTproducing strains of E. coli. The pathological process is triggered by the binding of the B-subunit of VTs to cell surface receptors whatever the following events are. To date, three glycosphingolipids containing common Gal␣1,4Gal-structure have been identified as potential receptors for VTs (35) . These glycosphingolipids include galabiosylceramide, Gb3, and P1 antigens. Tissue-specific expression of these structures are considered to play a role in the clinical spectrum of the illness seen in HUS (36, 37) . Actually, there have been a number of studies to suggest the apoptosis induction of cultured renal cells such as microvasucular endothelial cells (38) , proximal (39) and distal (40) tubular epithelial cells, as well as apoptosis of renal tubular cell in vivo (41) . On the other hand, human erythrocytes contain a fair amount of Gb3/CD77, but is hard to be recognized by antibodies. They showed no hemolysis even after incubation for 24 h with VT-2 in PBS at 100 ng/ml (data not shown), suggesting various modes of expression depending on tissues and cells.
Platelet is one of the major target cells in HUS, and a number of studies indicated marked consumption and/or activation of platelets leading to microthrombi and bleeding (42, 43) . However, whether VTs directly bind platelets has been controversial. It has been claimed that VTs do not directly affect platelet aggregation (16, 44) , or does not directly bind platelets (45) . On the other hand, direct binding and activation of platelets with VTs were demonstrated (17, 27) . Cooling et al. (27) defined a novel VT receptor (0.03) specific for platelets in addition to Gb3 on TLC binding, although actual involvement of 0.03 was not confirmed.
From the present findings, Gb3 expression on platelet cell surface is very low or null, and it appears unlikely that VTs directly induce platelet destruction. The results obtained in the present study suggest another mechanism for thrombocytopenia in HUS. Namely, the destruction of immature megakaryoblasts might take place leading to the arrest of platelet generation in the bone marrow and to thrombocytopenia in HUS patients.
If actual receptors on platelets to VTs are present, Gb3 and 0.03 might be potential receptors. Gb3/CD77 synthase can synthesize Gal␣1,4Gal-ceramide and Gb3, but not P1 (13) . The proposed structure of 0.03 is Gal␣1,4Gal␤1,3GalNAc␤1,3 Gal␣1,4Gal␤1,4Glc-ceramide (24) . Therefore, it appears unlikely that 0.03 is a product of Gb3/CD77 synthase. However, it was reported that the Gb3 level and 0.03 level were mutually correlated, suggesting 0.03 is a product of Gb3/CD77 synthase. This point remains to be clarified. In addition, surface expression of Gb3 and 0.03 (Gal-Gb5) on platelets remains to be analyzed. FIG. 9 . Localization of Gb3/CD77 and GPIIb-IIIa before and after treatment with TPA. A, the localization of Gb3/CD77 and GPIIb-IIIa before and after treatment with TPA was analyzed as described under "Experimental Procedures." B, platelets were stained after fixation with acetone using anti-Gb3/CD77 (top) and anti-GPIIbIIIa (bottom) as described in A. C, double staining of cytoplasmic granules with anti-Gb3/CD77 mAb and anti-GPIIb-IIIa mAb. Gb3/CD77 was detected with mAb 38.13 and Cy-3 anti-rat IgM, and GPIIb-IIIa was detected with mAb HPL-2 and FITC anti-mouse IgG as described under "Experimental Procedures." Ϫ8 M TPA for 1 day, then exposed to VT-2 (20 ng/ml). After 24 h, cytoplasmic DNA was prepared and run on an agarose gel as described under "Experimental Procedures." MEG-01 cells treated with and without TPA were compared. FIG. 11 . Scheme of megakaryoblast differentiation and expression of Gb3/CD77. Differentiation of megakaryoblasts causes alteration in the distribution of Gb3/CD77, resulting in less sensitivity to VTs. Open circle, GPIIb-IIIa; closed circle, Gb3/CD77.
Surface expression of Gb3/CD77 was relatively reduced despite the finding that the mRNA level of the Gb3/CD77 synthase gene was up-regulated during the induced differentiation of MEG-01. It seemed possible that the reduction of Gb3/CD77 expression was caused by increased crypticity due to co-expressed sialylglycoconjugates as previously described (25) . However, sialidase treatment of MEG-01 did not affect so much the expression levels of Gb3/CD77 as well as of GPIIb-IIIa at both TPA-treated and untreated conditions. Consequently, Gb3/CD77 appeared to have moved from the cell surface to the cytoplasm as shown in Fig. 9 , and been incorporated into the granules containing GPIIb-IIIa to form platelet precursors (Fig. 11) . If so, platelet precursors may already express both antigens before release. In fact, platelets showed co-expression of Gb3/CD77 and GPIIb-IIIa in the cytostaining. Taken together with the results of flow cytometry, platelets appear to express GPIIb-IIIa on the cell surface and to contain Gb3/CD77 inside of the "cells." However, the actual function of Gb3/CD77 antigen present inside the platelets remains unclear. Whether this intracellular Gb3/CD77 is accessible by outer ligands or antibodies remains to be clarified.
